The spatial folding of chromosomes inside the nucleus has regulatory effects on gene expression, yet the impact of genome reshuffling on this organization remains unclear. Here, we take advantage of chromosome conformation capture in combination with single-nucleotide polymorphism (SNP) genotyping and analysis of crossover events to study how the higher-order chromatin organization and recombination landscapes are affected by chromosomal fusions in the mammalian germ line.
We demonstrate that chromosomal fusions alter the nuclear architecture during meiosis, including an increased rate of heterologous interactions in primary spermatocytes, and alterations in both chromosome synapsis and axis length.
These disturbances in topology were associated with changes in genomic landscapes of recombination, resulting in detectable genomic footprints. Overall, we show that chromosomal fusions impact the dynamic genome topology of germ cells in two ways: (i) altering chromosomal nuclear occupancy and synapsis, and (ii) reshaping landscapes of recombination.
Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of HNSCC with or without HPV infection
Head and neck squamous cell carcinoma (HNSCC) are the sixth most common cancer type in the world. Human papillomavirus (HPV) infection is an emerging risk factor for HNSCC. Immune infiltration of HNSCC is linked to therapeutic results. This article aimed to decide whether variations in HPV status affect immune infiltration, molecular mechanism, and how these results vary in HNSCC patients.
We investigated the tumor-infiltrating immune cells (TIICs) and immune-related gene differences between HPV (+) and HPV (-) HNSCC. The gene expression quantification data of HNSCC and their clinical information were download from the TCGA database. Immune-related genes have been linked to the ImmPort platform.
After analyzed of 22 TIICs in the HNSCC tumor environment by CIBERSORT and further assessment, lower memory B cell and higher T cell regulatory were connected with better HPV (-) HNSCC outcome, higher activated memory CD4 T cell, higher T cell regulatory, and lower activated NK cell were linked with better HPV (+) result.
We finally got five forms of immune genes (CAMP, EDNRB, NTS, CXCL9, LHB) associated with HNSCC progression. Higher expressions of CAMP, EDNRB, and NTS were associated with increased overall survival in HPV (-) patients. Higher expression of CXCL9 and lower expression of LHB contributed to increased overall survival of HPV (+) patients.
There tend to be discrepancies in the cell structure of TIICs and immune-related genes in HPV (-) and HPV (+) HNSCC. These variances are typically too crucial for the therapeutic outcome of the patient and the development of the tumor. In specific, our sample established these candidate immune cells and immune-related genes as candidate reservoirs for further researches.
Multi-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage
The evolutionary pressure of endemic malaria and other erythrocytic pathogens has shaped variation in genes encoding erythrocyte structural and functional proteins, influencing responses to hemolytic stress during transfusion and disease.
We sought to identify such genetic variants in blood donors by conducting a genome-wide association study (GWAS) of 12,353 volunteer donors, including 1,483 African Americans, 1,477 Asians, and 960 Hispanics, whose stored erythrocytes were characterized by quantitative assays of in vitro osmotic, oxidative, and cold-storage hemolysis.
GWAS revealed 27 significant loci (p<5×10-8), many in candidate genes known to modulate erythrocyte structure, metabolism, and ion channels, including SPTA1, ALDH2, ANK1, HK1, MAPKAPK5, AQP1, PIEZO1, and SLC4A1/Band 3. GWAS of oxidative hemolysis identified variants in antioxidant enzymes including GLRX, GPX4, G6PD, and a novel golgi-transport protein SEC14L4.
Genome wide significant loci were also tested for association with the severity of steady state (baseline) in vivo hemolytic anemia in patients with sickle cell disease, with confirmation of identified SNPs in HBA2, G6PD, PIEZO1, AQP1 and SEC14L4. Many of the identified variants, such as those in G6PD, have previously been shown to impair erythrocyte recovery after transfusion, associate with anemia, or cause rare Mendelian human hemolytic diseases.
Candidate SNPs in these genes, especially in polygenic combinations, may affect RBC recovery after transfusion and modulate disease severity in hemolytic diseases, such as sickle cell disease and malaria.
stjosephs-hospital
Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer
Background: Treatment of patients with luminal metastatic breast cancer (MBC) has become even more complex over the last few years as molecular profiling has begun to alter disease management. It is well accepted that MBC is not curable but is treatable. Today we are able to prolong progression-free survival and partly overall survival with targeted and more individual treatment strategies adjusted according to the molecular subtype.
Summary: Genetic and genomic testing has become therapeutically relevant in luminal MBC and is therefore an integral component within the treatment spectrum. By now, germline testing of BRCABRCAPIK3CA mutations are inevitable elements in disease management and the current state of the art in luminal MBC patients.
Furthermore, testing of ESR1 resistance mutation, ERBB2 mutation, microsatellite instability, and neurotrophic tyrosine receptor kinase (NTRK) gene fusion (mainly in secretory breast cancer) has recently gained increasing attention. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities. The following review summarizes current developments in genetic and genomic testing in luminal MBC.
Key messages: In luminal MBC genomics have become an integral component within the spectrum of oncological treatment establishing novel therapeutic facilities. Further developments in treatment personalization adjusted according to the molecular subtype should become increasingly important in order to enhance the progress of de-escalation of chemotherapy in luminal MBC. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities.
HIV-P24 antigen array kit |
VArk-Lsx001 |
Creative Biolabs |
unit |
Ask for price |
Description: Fourth-generation HIV immunoassays detect viral p24 protein in the blood. |
Human HIV-1 And HIV-2 Antibodies Plus P24 Antigen Fourth-Generation ELISA Kit |
abx257575-05mg |
Abbexa |
0.5 mg |
Ask for price |
Human HIV-1 And HIV-2 Antibodies Plus P24 Antigen Fourth-Generation ELISA Kit |
abx257575-100g |
Abbexa |
100 µg |
EUR 468.75 |
Human HIV-1 And HIV-2 Antibodies Plus P24 Antigen Fourth-Generation ELISA Kit |
abx257575-1mg |
Abbexa |
1 mg |
Ask for price |
HIV-1 p17-p24 recombinant antigen. |
00172-V |
Virogen |
1 MG |
EUR 850 |
HIV-1 p17-p24 recombinant antigen. |
00172-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 p17-p24 recombinant antigen. |
HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations) |
0801200 |
Zeptometrix |
5 X 96T |
EUR 2563 |
HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations) |
801200 |
Zeptometrix |
5 X 96 Determinations |
EUR 2563 |
HIV-1 GAG P24 Recombinant Antigen |
00111-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 GAG P24 Recombinant Antigen |
00111-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV 1 p24 core recombinant antigen. |
00177-V |
Virogen |
1 MG |
EUR 850 |
HIV 1 p24 core recombinant antigen |
00177-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV 1 p24 core recombinant antigen. |
HIV 1 p24 core recombinant antigen |
00177-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV 1 p24 core recombinant antigen. |
HIV 1 p24 core recombinant antigen. |
00177-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV 1 p24 core recombinant antigen. |
HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations) |
0801008 |
Zeptometrix |
5 X 96T |
EUR 2505 |
Human HIV(1+2 antibodies plus p24 antigen (4th Generation) ELISA Kit |
EH4101 |
FN Test |
96T |
EUR 571.5 |
|
Description: Method of detection: Qualitative ;Reacts with: Homo sapiens;Sensitivity: Qualitative |
Mouse Anti Human Immunodeficiency Virus (HIV-1) p24 (1947) |
MAB12321-100 |
The Native Antigen Company |
0.1 |
EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for HIV-1 p24 |
Mouse Anti Human Immunodeficiency Virus (HIV-1) p24 (1947) |
MAB12321-500 |
The Native Antigen Company |
0.5 |
EUR 671.04 |
|
Description: Mouse monoclonal antibody specific for HIV-1 p24 |
Human HIV-1 p24 core protein (HIV-1 p24) antibody ELISA Kit |
NSL1389Hu |
Sunlong |
96 wells |
EUR 468 |
|
Human Immunodeficiency Virus p24 Protein [HIV-1/Clade B] |
REC31743-100 |
The Native Antigen Company |
0.1 |
EUR 496.27 |
Description: Recombinant HIV p24 protein (NCBI accession number ABO61536, AA35-265, L40I) produced in HEK293 cells. Protein carries a C-terminal His-tag.. Protein was purified by immobilised metal affinity and ion exchange chromatography from the pellet of transfected cells. |
Human Immunodeficiency Virus p24 Protein [HIV-1/Clade B] |
REC31743-500 |
The Native Antigen Company |
0.5 |
EUR 1363.78 |
Description: Recombinant HIV p24 protein (NCBI accession number ABO61536, AA35-265, L40I) produced in HEK293 cells. Protein carries a C-terminal His-tag.. Protein was purified by immobilised metal affinity and ion exchange chromatography from the pellet of transfected cells. |
HIV-1 p24 ELISA Kit |
Z7040001 |
Biochain |
1 kit |
EUR 865 |
Bovine HIV-1 p24 core protein(HIV-1 p24) Anti-body ELISA Kit |
NSL1181Bo |
Sunlong |
96 T |
EUR 528 |
|
Human HIV (1+2) antigen&antibody ELISA Kit |
EK11777 |
SAB |
96Т |
EUR 799 |
|
Human HIV (1+2) antigen&antibody ELISA Kit |
AE62582HU-48Tests |
Abebio |
48 Tests |
EUR 360 |
|
Description: Human (Homo sapiens) |
Human HIV (1+2) antigen&antibody ELISA Kit |
AE62582HU-96Tests |
Abebio |
96 Tests |
EUR 680 |
|
Description: Human (Homo sapiens) |
OPEF01414-1MG - Recombinant Human Immunodeficiency Virus 1 (HIV 1-p24) Antigen |
OPEF01414-1MG |
Aviva Systems Biology |
1mg |
EUR 2216 |
|
HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
00111-V |
Virogen |
1 MG |
EUR 850 |
HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
00111-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 p17/24/gp120 antigen |
00169-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV-1 p17/24/gp120 antigen |
00169-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
Astrovirus Antigen (Type 1) |
AS02-1000 |
The Native Antigen Company |
1.0 |
EUR 1654.65 |
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
Astrovirus Antigen (Type 1) |
AS02-200 |
The Native Antigen Company |
0.2 |
EUR 442.69 |
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
Canine Adenovirus 1 Antigen |
NAT41587-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Adenovirus Type 1, produced in A-72 cells. |
HIV-1 intergase antigen |
00199-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase). |
HIV-1 intergase antigen |
00199-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase). |
Herpes Simplex Virus 1 Antigen |
HS105-1000 |
The Native Antigen Company |
1.0 |
EUR 1178.79 |
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 1 Antigen |
HS105-200 |
The Native Antigen Company |
0.2 |
EUR 294.7 |
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Canine Adenovirus 1 and 2 Antigen |
NAT41589-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: A mixture of Canine Adenovirus Type 1 and Type 2, produced in A-72 cells. |
Herpes Simplex Virus 1 Lysate Antigen |
HS104-1000 |
The Native Antigen Company |
1.0 |
EUR 270.46 |
Description: A high concentration of HSV-1 particles and proteins from a clarified cell lysate. |
HIV-1 p24 Antibody |
20-abx137062 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
HIV-1 p24 Antibody |
abx023925-1mg |
Abbexa |
1 mg |
EUR 828 |
|
HIV-1 p24 Antibody |
abx023926-1mg |
Abbexa |
1 mg |
EUR 828 |
|
HIV-1 p24 Antibody |
abx021869-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
HIV-1 p24 Antibody |
abx021870-1mg |
Abbexa |
1 mg |
EUR 760.8 |
|
HIV-1 p24 Antibody |
abx021871-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
HIV-1 p24 Antibody |
abx021872-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
HIV-1 p24 Antibody |
abx021873-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
HIV-1 p24 Antibody |
abx021882-1mg |
Abbexa |
1 mg |
EUR 1178.4 |
|
HIV-1 p24 Antibody |
abx021883-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
HIV-1 p24 Antibody |
abx021886-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
HIV-1 p24 Antibody |
abx021887-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
HIV-1 p24 Antibody |
abx021888-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
HIV-1 p24 Antibody |
abx023027-1ml |
Abbexa |
1 ml |
EUR 693.6 |
|
HIV-1 p24 Antibody |
7313-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
HIV-1 p24 Antibody |
7313-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
HIV-1 p24 Antibody |
abx021869-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021869-80l |
Abbexa |
80 µl |
EUR 937.5 |
HIV-1 p24 Antibody |
abx021871-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021871-80l |
Abbexa |
80 µl |
EUR 937.5 |
HIV-1 p24 Antibody |
abx021872-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021872-80l |
Abbexa |
80 µl |
EUR 937.5 |
HIV-1 p24 Antibody |
abx021873-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021873-80l |
Abbexa |
80 µl |
EUR 937.5 |
HIV-1 p24 Antibody |
abx021882-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021882-80l |
Abbexa |
80 µl |
EUR 1237.5 |
HIV-1 p24 Antibody |
abx021883-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021883-80l |
Abbexa |
80 µl |
EUR 1237.5 |
HIV-1 p24 Antibody |
abx021886-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021886-80l |
Abbexa |
80 µl |
EUR 1237.5 |
HIV-1 p24 Antibody |
abx021887-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021887-80l |
Abbexa |
80 µl |
EUR 1587.5 |
HIV-1 p24 Antibody |
abx021888-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx021888-80l |
Abbexa |
80 µl |
EUR 1237.5 |
HIV-1 p24 Antibody |
abx023027-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody |
abx023027-80l |
Abbexa |
80 µl |
EUR 1012.5 |
Leptospira Biflexa Antigen (Strain Patoc 1) |
NAT41582-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
Leptospira Biflexa Antigen (Strain Patoc 1) |
NAT41582-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
HIV-1 p24 |
E62H002 |
EnoGene |
100ug |
EUR 255 |
HIV-1 p24 |
E5-00024 |
EnoGene |
1mg |
EUR 700 |
HIV-1 p24 |
ant-152 |
ProSpec Tany |
0.5mg |
EUR 275 |
Description: Mouse Anti HIV-1 p24 |
HIV-1 p24 |
hiv-006 |
ProSpec Tany |
100µg |
EUR 130 |
Description: Recombinant HIV-1 p24 |
Mouse Anti Human Immunodeficiency Virus (HIV-1) p17 (1981) |
MAB12320-100 |
The Native Antigen Company |
0.1 |
EUR 310.01 |
|
Description: Mouse monoclonal antibody specific for HIV-1 p17 |
Mouse Anti Human Immunodeficiency Virus (HIV-1) p17 (1981) |
MAB12320-500 |
The Native Antigen Company |
0.5 |
EUR 770.55 |
|
Description: Mouse monoclonal antibody specific for HIV-1 p17 |
HIV-1 gag recombinant antigen |
8934 |
Virostat |
100 ug |
EUR 542.86 |
Description: This is HIV-1 gag recombinant antigen for ELISA,WB. |
HIV-1 nef recombinant antigen |
8941 |
Virostat |
100 ug |
EUR 477.6 |
Description: This is HIV-1 nef recombinant antigen for ELISA,WB. |
HIV-1 tat recombinant antigen |
00110-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 tat recombinant antigen |
00110-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 nef recombinant antigen |
00112-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 nef recombinant antigen |
00112-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 gp41 recombinant antigen |
9000 |
Virostat |
100 ug |
EUR 484.13 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
9001 |
Virostat |
100 ug |
EUR 484.13 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
8908 |
Virostat |
100 ug |
EUR 673.36 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
8933 |
Virostat |
100 ug |
EUR 477.6 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen. |
00170-V |
Virogen |
1 MG |
EUR 850 |
HIV-1 gp41 recombinant antigen, |
00170-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 gp41 recombinant antigen. |
HIV-1 gp41 recombinant antigen, |
00170-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 gp41 recombinant antigen. |
HIV-1 gp41 recombinant antigen. |
00170-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 gp41 recombinant antigen. |
Borrelia Afzelii Antigen |
NAT41583-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Afzelii Antigen |
NAT41583-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Garinii Antigen |
NAT41584-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Garinii Antigen |
NAT41584-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Brucella Abortus Antigen |
NAT41599-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Brucella abortus lysate, produced by fermentation. |
Brucella Abortus Antigen |
NAT41599-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Brucella abortus lysate, produced by fermentation. |
Candida Albicans Antigen |
NAT41601-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
Candida Albicans Antigen |
NAT41601-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
Canine Parvovirus Antigen |
NAT41594-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Parvovirus, produced in CRFK cells. |
Canine Coronavirus Antigen |
NAT41590-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Coronavirus produced in A-72 cells. |
Feline Calicivirus Antigen |
NAT41595-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Feline Calicivirus produced in FC 3TG cells. |
Helicobacter Pylori Antigen |
NAT41603-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
Helicobacter Pylori Antigen |
NAT41603-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
Campylobacter Jejuni Antigen |
NAT41600-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
Campylobacter Jejuni Antigen |
NAT41600-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
Chlamydia Trachomatis Antigen |
CT022-1000 |
The Native Antigen Company |
1.0 |
EUR 378.9 |
Description: Chlamydia trachomatis antigens from clarified cell lysate. |
Neisseria Gonorrhoeae Antigen |
NG01-1000 |
The Native Antigen Company |
1.0 |
EUR 378.9 |
Description: Homogenised lysate of pure bacteria. |
Mycoplasma Pneumoniae Antigen |
MP901-1000 |
The Native Antigen Company |
1.0 |
EUR 1010.39 |
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
Mycoplasma Pneumoniae Antigen |
MP901-200 |
The Native Antigen Company |
0.2 |
EUR 270.46 |
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
Echovirus Antigen, Recombinant |
REC31776-100 |
The Native Antigen Company |
0.1 |
EUR 276.84 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
Echovirus Antigen, Recombinant |
REC31776-500 |
The Native Antigen Company |
0.5 |
EUR 1043.56 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
Trichomonas Vaginalis Antigen |
TV01-1000 |
The Native Antigen Company |
1.0 |
EUR 421 |
Description: Washed & lysed suspension of whole protozoa |
Echinococcus Granulosus Antigen |
NAT41602-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
Echinococcus Granulosus Antigen |
NAT41602-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
Enterovirus Antigen, Recombinant |
REC31772-100 |
The Native Antigen Company |
0.1 |
EUR 276.84 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
Enterovirus Antigen, Recombinant |
REC31772-500 |
The Native Antigen Company |
0.5 |
EUR 1043.56 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
Cytomegalovirus Purified Antigen |
CMV-HP-100 |
The Native Antigen Company |
0.1 |
EUR 318.94 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Cytomegalovirus Purified Antigen |
CMV-HP-1000 |
The Native Antigen Company |
1.0 |
EUR 2096.06 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Cytomegalovirus Purified Antigen |
CMV-HP-500 |
The Native Antigen Company |
0.5 |
EUR 1279.58 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Yersinia pestis V antigen |
REC32028-100 |
The Native Antigen Company |
0.1 |
EUR 491.53 |
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
Yersinia pestis V antigen |
REC32028-500 |
The Native Antigen Company |
0.5 |
EUR 2421.37 |
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
HIV p24 Antibody |
abx021867-1mg |
Abbexa |
1 mg |
EUR 1612.8 |
|
HIV p24 Antibody |
abx021868-1mg |
Abbexa |
1 mg |
EUR 1612.8 |
|
HIV p24 Antibody |
abx021867-400l |
Abbexa |
400 µl |
Ask for price |
HIV p24 Antibody |
abx021867-80l |
Abbexa |
80 µl |
EUR 937.5 |
HIV p24 Antibody |
abx021868-400l |
Abbexa |
400 µl |
Ask for price |
HIV p24 Antibody |
abx021868-80l |
Abbexa |
80 µl |
EUR 1500 |
Canine Herpes Virus Antigen |
NAT41592-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Herpes virus, produced in MDCK cells. |
HIV-1 p24 (HIV-1) recombinant |
GWB-FE5FE0 |
GenWay Biotech |
0.1 mg |
Ask for price |
Canine Adenovirus 2 Antigen |
NAT41588-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Adenovirus Type 2, produced in A-72 cells. |
Canine Distemper Virus Antigen |
NAT41591-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Distemper virus, produced in SL-29 cells. |
HIV-1 p17/24/gp120-gp41 recombinant antigen. |
00168-V |
Virogen |
1 MG |
EUR 850 |
HIV-1 p17/24/gp120-gp41 recombinant antigen, |
00168-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p17/24/gp120-gp41 recombinant antigen, |
00168-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p17/24/gp120-gp41 recombinant antigen. |
00168-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV 1 envelope recombinant antigen |
00176-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
HIV 1 envelope recombinant antigen |
00176-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
Norovirus GII.4 VP1 Antigen |
REC31620-100 |
The Native Antigen Company |
0.1 |
EUR 302.36 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Norovirus GII.4 VP1 Antigen |
REC31620-1000 |
The Native Antigen Company |
1.0 |
EUR 1830.71 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Norovirus GII.4 VP1 Antigen |
REC31620-500 |
The Native Antigen Company |
0.5 |
EUR 1066.53 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Canine Parainfluenza Virus Antigen |
NAT41593-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Parainfluenza virus antigen, produced in MDCK cells. |
Feline Panleukopenia Virus Antigen |
NAT41597-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Feline Panleukopenia Virus (FPLV; feline parvovirus) antigen, produced in CRFK cells. |
HIV-1 p24 Antibody (HRP) |
abx023029-1ml |
Abbexa |
1 ml |
EUR 886.8 |
|
HIV-1 p24 Antibody [8G9] |
PM-6335-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] |
PM-6335-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] |
PM-6585-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] |
PM-6585-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody (HRP) |
abx023029-400l |
Abbexa |
400 µl |
Ask for price |
HIV-1 p24 Antibody (HRP) |
abx023029-80l |
Abbexa |
80 µl |
EUR 1150 |